A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs with Moderately to Severely Active Rheumatoid Arthritis
To investigate the efficacy and safety of a study drug called baricitinib when used to treat severe active Rheumatoid Arthritis (RA) in those with inadequate response to conventional Disease-Modifying Antirheumatic Drugs (cDMARDs).
Moderate to Severe Active Rheumatoid Arthritis (RA)
Males and Females, age 18 and older, with RA who have had an inadquate response to cDMARDs
18 - 99
Healthy Volunteers Needed
Duration of Participation
Participation could last at least 24+ weeks - with the possibility of entering a long-term extension study.
Eli Lilly and Company
Subjects will receive $42 for each study visit completed. If they complete the entire study they could receive up to $504.